ATE342054T1 - Verfahren und zusammansetzung zur behandlung von krebs - Google Patents

Verfahren und zusammansetzung zur behandlung von krebs

Info

Publication number: ATE342054T1
Authority: AT; Austria
Prior art keywords: composition; lapachone; beta; administration; treating cancer
Prior art date: 1999-04-14

Application number

AT00922237T

Other languages

English (en)

Inventor

Arthur B Pardee

Chiang J Li

You-Zhi Li

Original Assignee

Dana Farber Cancer Inst Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-14

Filing date

2000-04-14

Publication date

2006-11-15

2000-04-14 Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE342054T1 publication Critical patent/ATE342054T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title 1
QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 abstract 4
229930012538 Paclitaxel Natural products 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229960001592 paclitaxel Drugs 0.000 abstract 2
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
230000010190 G1 phase Effects 0.000 abstract 1
230000018199 S phase Effects 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
231100000161 signs of toxicity Toxicity 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)

AT00922237T 1999-04-14 2000-04-14 Verfahren und zusammansetzung zur behandlung von krebs ATE342054T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12926199P	1999-04-14	1999-04-14

Publications (1)

Publication Number	Publication Date
ATE342054T1 true ATE342054T1 (de)	2006-11-15

Family

ID=22439161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00922237T ATE342054T1 (de)	1999-04-14	2000-04-14	Verfahren und zusammansetzung zur behandlung von krebs

Country Status (8)

Country	Link
US (3)	US6664288B1 (de)
EP (1)	EP1181013B1 (de)
JP (2)	JP2002541200A (de)
AT (1)	ATE342054T1 (de)
CA (1)	CA2369303A1 (de)
DE (1)	DE60031268T2 (de)
ES (1)	ES2273688T3 (de)
WO (1)	WO2000061142A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US7820718B1 (en) *	1999-04-07	2010-10-26	Roger Williams Hospital	Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
US20050192360A1 (en) *	1999-04-14	2005-09-01	Li Chiang J.	Method of treatment of pancreatic cancer
CA2369303A1 (en) *	1999-04-14	2000-10-19	Arthur B. Pardee	Method and composition for the treatment of cancer
US20050222246A1 (en) *	1999-04-14	2005-10-06	Li Chiang J	Beta-lapachone is a broad spectrum anti-cancer agent
AU1186202A (en) *	2000-10-05	2002-04-15	George Q Daley	Methods of inducing cancer cell death and tumor regression
AU2002234165A1 (en)	2000-11-03	2002-05-27	Tularik, Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) *	2000-11-03	2005-11-10	Amgen Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
CA2428425A1 (en) *	2000-11-07	2002-08-01	Dana-Farber Cancer Institute, Inc.	Method of treating hematologic tumors and cancers
US20050197405A1 (en) *	2000-11-07	2005-09-08	Li Chiang J.	Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7070797B2 (en)	2000-11-07	2006-07-04	Dana Farber Cancer Institute, Inc.	Method of treating hematologic tumors and cancers
US20020183266A1 (en) *	2001-03-15	2002-12-05	Aventis Pharma, S.A.	Combination comprising combretastatin and anticancer agents
US6756063B2 (en) *	2001-03-29	2004-06-29	Zoltan Laboratories, Llc	Methods and compositions for the treatment of human and animal cancers
US20030212147A1 (en) *	2001-07-12	2003-11-13	Chung Sum Man Stephen	Enzyme activated chemotherapy of liver cancer
US7074824B2 (en)	2001-07-31	2006-07-11	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en)	2001-07-31	2005-11-08	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
US20030100594A1 (en) *	2001-08-10	2003-05-29	Pharmacia Corporation	Carbonic anhydrase inhibitor
US20030220376A1 (en) *	2001-08-10	2003-11-27	Pharmacia Corporation	Methods for treating carbonic anhydrase mediated disorders
US20040067992A1 (en) *	2001-08-10	2004-04-08	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
AU2003235761A1 (en) *	2002-01-14	2003-07-24	Novartis Ag	Combinations comprising epothilones and anti-metabolites
AU2007200677B2 (en) *	2002-01-14	2009-10-29	Novartis Ag	Combinations comprising epothilones and anti-metabolites
US6816571B2 (en) *	2002-02-06	2004-11-09	L-3 Communications Security And Detection Systems Corporation Delaware	Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
AU2003228666A1 (en) *	2002-04-23	2003-11-10	Case Western Reserve University	Lapachone delivery systems, compositions and uses related thereto
EP1575556A2 (de) *	2002-05-20	2005-09-21	Kosan Biosciences, Inc.	Verfahren zur verabreichung von epothilon d
AU2003254029A1 (en) *	2002-07-17	2004-02-02	Arqule, Inc.	Activated checkpoint therapy and methods of use thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
DE60310916T2 (de)	2002-08-23	2007-11-15	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
WO2004032872A2 (en) *	2002-10-09	2004-04-22	Kosan Biosciences, Inc.	Epo D + 5-FU/GEMCITABINE
JP2006508147A (ja) *	2002-11-18	2006-03-09	アルキュール，インコーポレイテッド	新規ラパコン化合物およびその使用方法
EP1575580A4 (de) *	2002-12-02	2009-06-10	Arqule Inc	Verfahren zur behandlung von karzinomen
US7670627B2 (en) *	2002-12-09	2010-03-02	Salvona Ip Llc	pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2005052184A1 (en) *	2003-11-26	2005-06-09	Amadeo Parissenti	Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment
CA2546445A1 (en)	2003-11-26	2005-06-16	Arqule, Inc.	Use of beta-lapachone for protecting against radiation injury
EP2033639A2 (de)	2004-02-20	2009-03-11	Arqule, Inc.	Beta-Lapachon zur Behandlung von Dickdarmkrebs
EP1722775A1 (de)	2004-02-20	2006-11-22	Arqule, Inc.	Verwendung von beta-lapachon zur behandlung von hämatologischen tumoren
JP2007523193A (ja) *	2004-02-20	2007-08-16	アークル・インコーポレーテツド	膵癌の治療のためのβ−ラパコンの使用
US20050187288A1 (en) *	2004-02-20	2005-08-25	Chiang Li	Beta-lapachone and methods of treating cancer
US20050192247A1 (en) *	2004-02-23	2005-09-01	Li Chiang J.	Method of treating cancers
US20040224019A1 (en) *	2004-03-03	2004-11-11	Adi Shefer	Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US8415315B2 (en)	2004-05-06	2013-04-09	University Of Central Florida Research Foundation, Inc.	Methods and compositions for inhibiting the proliferation of cancer cells
US8614228B2 (en)	2004-08-11	2013-12-24	Arqule, Inc.	Quinone prodrug compositions and methods of use
WO2006020719A2 (en) *	2004-08-11	2006-02-23	Arqule, Inc.	Aminoacid conjugates of beta - lapachone for tumor targeting
DE102005055385A1 (de) *	2004-12-09	2006-06-14	Bayer Healthcare Ag	Arzneimittel zur hygienischen Applikation im Ohr
US20060204981A1 (en)	2005-01-07	2006-09-14	Chiang Li	Compositions for modulation of PARP and methods for screening for same
MX2008012717A (es) *	2006-04-05	2008-10-14	Novartis Ag	Combinaciones de agentes terapeuticos para el tratamiento de cancer.
JP2009538298A (ja) *	2006-05-26	2009-11-05	アークルインコーポレイテッド	新規のラパコン化合物およびその使用方法
TW200824692A (en)	2006-08-21	2008-06-16	Arqule Inc	Novel lapachone compounds and methods of use thereof
MX2009011822A (es)	2007-04-30	2010-01-14	Arqule Inc	Hidroxi sulfonatos de compuestos de quinonicos y sus usos.
US8067459B2 (en)	2007-10-16	2011-11-29	Arqule, Inc.	Lapachone compounds and methods of use thereof
US7808078B2 (en) *	2008-08-26	2010-10-05	Sanyo Electric Co., Ltd.	Semiconductor device and manufacturing method thereof
US8618302B2 (en)	2010-01-06	2013-12-31	Joseph P. Errico	Methods and compositions of targeted drug development
US8658170B2 (en)	2010-01-06	2014-02-25	Joseph P. Errico	Combination therapy with MDM2 and EFGR inhibitors
ES2671248T3 (es)	2010-09-22	2018-06-05	The Board Of Regents Of The University Of Texas System	Métodos para tratar el cáncer que comprenden un guiado por NQO1
WO2012162627A1 (en) *	2011-05-26	2012-11-29	The General Hospital Corporation	Treatment of angiogenic- or vascular-associated diseases
BRPI1106509A2 (pt) *	2011-10-25	2013-11-19	Universidade Federal Do Rio De Janeiro Ufrj	Uso das pironofatoquinona como antiviral; composição farmacêutica contendo as piranonaftoquinonas; medicamento contendo as piranonaftoquinonas para tratamento de infecções causadas por virus da dengue
CN104971351A (zh) *	2014-04-08	2015-10-14	清华大学	药物组合物及其应用
US10537545B2 (en)	2015-07-20	2020-01-21	Rutgers, The State University Of New Jersey	Ceramide derivatives as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5763625A (en) *	1995-04-25	1998-06-09	Wisconsin Alumni Research Foundation	Synthesis and use of β-lapachone analogs
CA2369303A1 (en) *	1999-04-14	2000-10-19	Arthur B. Pardee	Method and composition for the treatment of cancer

2000
- 2000-04-14 CA CA002369303A patent/CA2369303A1/en not_active Abandoned
- 2000-04-14 WO PCT/US2000/010169 patent/WO2000061142A1/en not_active Ceased
- 2000-04-14 JP JP2000610475A patent/JP2002541200A/ja active Pending
- 2000-04-14 DE DE60031268T patent/DE60031268T2/de not_active Expired - Fee Related
- 2000-04-14 ES ES00922237T patent/ES2273688T3/es not_active Expired - Lifetime
- 2000-04-14 EP EP00922237A patent/EP1181013B1/de not_active Expired - Lifetime
- 2000-04-14 US US09/958,479 patent/US6664288B1/en not_active Expired - Fee Related
- 2000-04-14 AT AT00922237T patent/ATE342054T1/de not_active IP Right Cessation
2003
- 2003-10-09 US US10/683,199 patent/US6875745B2/en not_active Expired - Fee Related
2005
- 2005-03-01 US US11/069,637 patent/US20050171031A1/en not_active Abandoned
2008
- 2008-09-01 JP JP2008224161A patent/JP2009051841A/ja active Pending

Also Published As

Publication number	Publication date
ES2273688T3 (es)	2007-05-16
US20050171031A1 (en)	2005-08-04
CA2369303A1 (en)	2000-10-19
WO2000061142A1 (en)	2000-10-19
US6664288B1 (en)	2003-12-16
DE60031268D1 (de)	2006-11-23
US6875745B2 (en)	2005-04-05
EP1181013B1 (de)	2006-10-11
US20040087610A1 (en)	2004-05-06
JP2009051841A (ja)	2009-03-12
EP1181013A4 (de)	2004-07-07
JP2002541200A (ja)	2002-12-03
DE60031268T2 (de)	2007-05-24
EP1181013A1 (de)	2002-02-27

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE342054T1 (de)	2006-11-15	Verfahren und zusammansetzung zur behandlung von krebs
DE69928567D1 (de)	2005-12-29	Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs
RU94029662A (ru)	1996-07-10	Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE421322T1 (de)	2009-02-15	Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
GB0305152D0 (en)	2003-04-09	Organic compounds
EP1622608A4 (de)	2010-11-10	Zusammensetzungen und verfahren zur behandlung von krebs
GEP20043322B (en)	2003-12-10	C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
ATE322265T1 (de)	2006-04-15	Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2002058694A3 (en)	2003-12-04	Method of treating hematologic tumors and cancers using beta lapachone
ATE260282T1 (de)	2004-03-15	Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DK1056704T3 (da)	2003-08-18	Antitumormidler
ATE485818T1 (de)	2010-11-15	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
EA200600992A1 (ru)	2006-10-27	Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
DE69815100D1 (de)	2003-07-03	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
ATE393624T1 (de)	2008-05-15	Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE359800T1 (de)	2007-05-15	Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
BRPI0410026A (pt)	2006-04-25	derivados de 3-amino-croman quinolina
WO2005102997A8 (en)	2006-11-23	3,4-disubstituted maleimides for use as vascular damaging agents
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004014125D1 (de)	2008-07-10	Ruthenium(ii)-komplexe zur behandlung von tumoren
DE50200757D1 (de)	2004-09-09	Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
AU2003266031A1 (en)	2004-04-23	Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours
ATE327240T1 (de)	2006-06-15	2ß OXO-VORUSCHARIN UND DERIVATEN
HK1154859A1 (zh)	2012-05-04	用於治療癌症的異吲哚啉化合物